ArticleTransboundary and emerging diseases2020
Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study.
Article in Transboundary and emerging diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves.Journal of medical virology · 2021Pooled it
- The Prognostic Value of Hyponatremia for Predicting Poor Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review.Annals of the New York Academy of Sciences · 2021Pooled it
- Pregnancy and Breastfeeding During COVID-19 Pandemic: A Systematic Review of Published Pregnancy Cases.Frontiers in public health · 2020Pooled it
- Case-control study to identify risk factors for SARS-CoV-2 infection among university students in the northeastern USA.Transboundary and emerging diseases · 2022Article
- Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Review
- Pulmonary Complications after COVID-19.Life (Basel, Switzerland) · 2022Article
- Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review.Cytokine & growth factor reviews · 2022Review
- The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection.Infection and drug resistance · 2022Article
- Clinical Characteristics of Omicron SARS-CoV-2 Variant Infection After Non-mRNA-Based Vaccination in China.Frontiers in microbiology · 2022Article
- Post-COVID syndrome: pulmonary complicationsTurkish journal of medical sciences · 2021Review
- The impact of COVID-19 during pregnancy on maternal and neonatal outcomes: a systematic review.EMBnet.journal · 2021Article
- Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study.BMC infectious diseases · 2021Article
- Genomic Epidemiology of SARS-CoV-2 From Mainland China With Newly Obtained Genomes From Henan Province.Frontiers in microbiology · 2021Article
- How to Reduce the Transmission Risk of COVID-19 More Effectively in New York City: An Age-Structured Model Study.Frontiers in medicine · 2021Article
- Protracted viral shedding and viral load are associated with ICU mortality in Covid-19 patients with acute respiratory failure.Annals of intensive care · 2020Article
- Clinical Features of COVID-19 in Uzbekistan.Journal of Korean medical science · 2020Article
- Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study.Transboundary and emerging diseases · 2020Article
- Initial Inoculum and the Severity of COVID-19: A Mathematical Modeling Study of the Dose-Response of SARS-CoV-2 Infections.Epidemiologia (Basel, Switzerland) · 2020Article
- The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis.Clinical epidemiology and global healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 10 institutions in 3 countries.
Funding
Abstract
Currently, COVID-19 has been reported in nearly all countries globally. To date, little is known about the viral shedding duration, clinical course and treatment efficacy of COVID-19 near Hubei Province, China. This multicentre, retrospective study was performed in 12 hospitals in Henan and Shaanxi Provinces from 20 January to 8 February 2020. Clinical outcomes were followed up until 26 March 2020. The viral shedding duration, full clinical course and treatment efficacy were analysed in different subgroups of patients. A total of 149 COVID-19 patients were enrolled. The median age was 42 years, and 61.1% (91) were males. Of them, 133 (89.3%) had fever, 131 of 144 (91%) had pneumonia, 27 (18.1%) required intensive care unit (ICU) management, 3 (2%) were pregnant, and 3 (2%) died. Two premature newborns were negative for SARS-CoV-2. In total, the median SARS-CoV-2 shedding period and clinical course were 12 (IQR: 9-17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16-24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively, and ICU patients had longer median viral shedding periods (21 [17-24] versus 11 [9-15]) and clinical courses (30 [22-33] vs. 19 [15.8-22]) than non-ICU patients (both p < .0001). SARS-CoV-2 clearances occurred at least 2 days before fatality in 3 non-survivors. Current treatment with any anti-viral agent or combination did not present the benefit of shortening viral shedding period and clinical course (all p > .05) in real-life settings. In conclusion, the viral shedding duration and clinical course in Henan and Shaanxi Provinces were shorter than those in Hubei Province, and current anti-viral therapies were ineffective for shortening viral shedding duration and clinical course in real-world settings. These findings expand our knowledge of the SARS-CoV-2 infection and may be helpful for management of the epidemic outbreak of COVID-19 worldwide. Further studies concerning effective anti-viral agents and vaccines are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.